this post was submitted on 16 Nov 2023
62 points (100.0% liked)

Technology

34702 readers
735 users here now

This is the official technology community of Lemmy.ml for all news related to creation and use of technology, and to facilitate civil, meaningful discussion around it.


Ask in DM before posting product reviews or ads. All such posts otherwise are subject to removal.


Rules:

1: All Lemmy rules apply

2: Do not post low effort posts

3: NEVER post naziped*gore stuff

4: Always post article URLs or their archived version URLs as sources, NOT screenshots. Help the blind users.

5: personal rants of Big Tech CEOs like Elon Musk are unwelcome (does not include posts about their companies affecting wide range of people)

6: no advertisement posts unless verified as legitimate and non-exploitative/non-consumerist

7: crypto related posts, unless essential, are disallowed

founded 5 years ago
MODERATORS
you are viewing a single comment's thread
view the rest of the comments
[–] [email protected] 3 points 11 months ago

This is the best summary I could come up with:


In a small initial test in people, researchers have shown that a single infusion of a novel gene-editing treatment can reduce cholesterol, the fatty substance that clogs and hardens arteries over time.

This places a very heavy treatment burden on patients, providers, and the health care system,” said Andrew Bellinger, chief scientific officer of Verve Therapeutics, at a news conference over the weekend.

In a study published in the journal Circulation earlier this year, researchers from the company showed that the approach lowered bad cholesterol 49 to 69 percent in monkeys, depending on the dosage they received.

While the participants already had severe coronary artery disease, and some had previously experienced a heart attack, the company aims to eventually treat younger patients in order to prevent these outcomes.

Sanjay Rajagopalan, director of the Cardiovascular Research Institute at Case Western Reserve University School of Medicine, calls the results a “very exciting” proof of concept.

But Rajagopalan, who wasn’t involved in the Verve study, says the main concern about any Crispr-based approach is the potential for off-target effects, in which unwanted cells or genes would unintentionally be edited.


The original article contains 730 words, the summary contains 186 words. Saved 75%. I'm a bot and I'm open source!